Skip to Content
Merck
CN
All Photos(4)

Documents

Safety Information

SAB4200420

Sigma-Aldrich

Anti-Lamin A, mature antibody, Mouse monoclonal

enhanced validation

clone 4A4, purified from hybridoma cell culture

Sign Into View Organizational & Contract Pricing

Synonym(s):
Anti-LMN1, Anti-LMNA, Anti-Lamin A/C, Anti-Prelamin-A/C, Monoclonal Anti-Lamin A, mature antibody produced in mouse
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

4A4, monoclonal

form

buffered aqueous solution

mol wt

antigen ~72 kDa

species reactivity

human

enhanced validation

independent
Learn more about Antibody Enhanced Validation

concentration

~1.0 mg/mL

technique(s)

indirect immunofluorescence: 0.25-0.5 μg/mL using human HeLa cells
western blot: 0.25-0.5 μg/mL using whole extracts of human HeLa cells

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... LMNA(4000)

General description

Lamin A is encoded by the gene with exons 1–12, mapped on human chromosome 1q21-22. The encoded protein is a major component of the inner nuclear membrane lamina. Lamin A is expressed in variety of tissues, including adult heart and skeletal muscle.

Immunogen

synthetic peptide corresponding to the C-terminus of mature human Lamin A.

Application

Monoclonal Anti-Lamin A, mature antibody produced in mouse has been used in immunohistochemistry.

Biochem/physiol Actions

Lamin A can be used as a biomarker for cancer diagnosis and prognosis. It also plays a major role in maintaining cardiac homeostasis. Mutation in the gene is associated with Emery-Dreifuss muscular dystrophy (EDMD-AD) and Hutchinson–Gilford progeria syndrome (HGPS). In addition, variation in the gene expression also leads to various disorders such as, lipodystrophy, progeria, muscular dystrophy, neuropathy and cardiomyopathy.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C.
Patni N
American Journal of Medical Genetics. Part A, 173, 2517-2521 (2017)
Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic phenomenon in Alzheimer's disease.
Mastroeni D
Neurobiology of Aging, 36, 3121-3129 (2015)
Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy.
Cao H and Hegele RA
Human Molecular Genetics, 9, 109-112 (2000)
Increased ventilatory response to exercise in symptomatic and asymptomatic LMNA mutation carriers: a follow-up study.
Ollila L
Clinical Physiology and Functional Imaging, 37, 8-16 (2017)
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
Eriksson M
Nature, 423, 293-298 (2003)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service